Skip to main content

COVID-19 Topic Center

CAR-T Therapies Literature Review

First Report Managed Care
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA Health Forum, researchers examine if CAR-T therapies can…
First Report Managed Care
Acute myeloid leukemia (AML) is an aggressive type of blood cancer in which the bone marrow makes abnormal myeloblasts, or immature white blood cells, resulting in low healthy white cell count. AML is also sometimes referred to as acute myelogenous leukemia, acute myeloblastic leukemia, acute…
First Report Managed Care
Rheumatoid arthritis (RA) continues to affect as many as 1.5 million adults in the United States.1 Women are 2 to 3 times as likely to be affected as men.2 The burden of this disease is high; patients with RA have a 60%-70% higher mortality risk compared with those in the general population, and…
First Report Managed Care
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system.1,2 According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well understood.1 Estimates put the incidence of NETs at 6.98…
Back to Top